Curis’s stock rises as analysts see ‘the next Pharmacyclics’
Shares of Curis Inc. CRIS, gained nearly 6% premarket on Friday after Truist Securities analysts initiated coverage of the cancer-focused biotech company with a buy rating. Curis, whose lead drug candidate is cancer therapy emavusertib, is “the next Pharmacyclics,” Truist analysts led by Robyn…
#curisinc #truistsecurities #karnauskas #imbruvica #abbvieinc #truist #lymphoma #nonhodgkin